Silly it is! Look forward to seeing if some of this does relate...

Silly it is! Look forward to seeing if some of this does relate to 30 June.

I can't really say our 'sophisticated and professional investors' have helped the cause much. Yes - money in the bank but they have also sold into anything that popped it's head above .015 especially on the day of the OMRON announcement.

Now is seems that the investors that brought into the OMRON announcement are cutting their losses.

Yes - there has been some great announcements over the last year - however - sometimes these announcements have been equally frustrating in their lack of follow up and ability to find there way to the revenue line - for example: -

15 Jun 10 - Demand has shown steady increase 'such that sales for the last 3 months are expected to be US$300,000' - 'expected that this rate of sales will continue to increase over the coming quarters'

28 Oct 10 - KSX appoints Mr Bill Nicklin as Manufacturing Consultant

9 Nov 10 - we shipped more hardware in the month of October than in the previous three months combined
- expect to expand our manufacturing capacity by up to 5 times by the end of Q2, 2011.

27 Jan 11 - continued our assessment and qualification of an appropriate strategic manufacturing partner 'we will shortly be in a position to announce this new partnership'
- number of our European distributors are making new commitments to our products by hiring dedicated clinical and sales specialists to handle our products
* test market sites of WHolter Home Sleep test- launched 10 sites in US with prospects of more in Q1 2011.

1 Mar 11 - Service Agreement with Childrens Hospital

2 Mar 11 - Launch Home testing in Australia - launch expected to be completed within 90 days of announcement

22 Mar 11 - JV for At-Home Monitoring of Nocturnal Asthma (HSS)

4 May 11 - coming weeks we will release more details about the status of our US listing and will identify the investment banking team to assist us in executing our US based strategy

To be fair - the company forecast sales of under $1m in 2011 ($2.5m in 2011 calendar year) - rising up to over $5m in 2012.

They are attracting the right people with the right skills - and it seems that where the product has been introduced it has be accepted and embraced.

The fact is it is a new product in a conservative market - adoption rate is directly related to KSX's ability to educate the end users. However our deal with OMRON (and possibly Philips??) confirm that the big companies value our products.

Totally agree with proactiveinvestors.com.au on this one 'At a market capitalization of just $10.3 million for KarmelSonix , this is very light for a company on the cusp of potential domination of a healthcare diagnostic segment that has similarities to the ascent of ResMed in its particular market.'